A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
40actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-11 | actual | When the study began enrolling |
| Primary completion | 2026-06-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-19 | actual | The whole study's end, after follow-up |
| First posted | 2026-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ABBV-8736
- Drug: ABBV-8736
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs)
measured Up to At Least 3 Months
Maximum Observed Serum Concentration (Cmax) of ABBV-8736
measured Up to At Least 3 Months
Time to Maximum Observed Serum Concentration (Tmax) of ABBV-8736
measured Up to At Least 3 Months
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time Last (AUClast) of ABBV-8736
measured Up to At Least 3 Months
AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-8736
measured Up to At Least 3 Months
Terminal Phase Elimination Rate Constant (β) of ABBV-8736
measured Up to At Least 3 Months
Terminal Elimination Half-Life (t1/2) of ABBV-8736
measured Up to At Least 3 Months
Apparent Clearance of the Analyte in Serum (CL) of ABBV-8736
measured Up to At Least 3 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed